Faulty reasoning: "CytoDyn, with it’s lead
Post# of 80081
"CytoDyn, with it’s lead drug leronlimab, is the only company to successfully complete a Phase 3 randomized clinical trial for severe-to-critically ill Covid-19 patients with mortality as an endpoint!!! You don’t have to be a virologist to know that a drug with a mortality as a primary endpoint completes two DSMC reviews with no changes, to know that means the drug is working as it was intended in the trial design."
Read More: https://investorshangout.com/post/view?id=602...z6kBe7oKJM

